Evaxion Biotech (EVAX) is pursuing a significant expected enhancement of its equity and capital structure through a conversion of debt into equity. Evaxion is currently in advanced discussions with the European Investment Bank, EIB, about conversion of EUR 3.5M out of Evaxion’s EUR 7M loan with EIB into an equity-type instrument. A conversion is expected to increase Evaxion’s equity by $3.7 million immediately upon completion and constitutes an important part of Evaxion’s plan to ensure ongoing compliance with the Nasdaq listing requirements. Evaxion has no debt besides the EIB-loan, so the conversion would also substantially reduce the company’s overall liabilities, simplify its balance sheet and improve its financial flexibility and cash flow.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Biotech Advances AI-Driven Precision Cancer Vaccine Concept
- Evaxion Biotech establishes new Ai-derived precision cancer vaccine concept
- Evaxion Biotech announces strategic milestones for 2025
- Evaxion Biotech Unveils 2025 Strategic Milestones
- Evaxion Biotech Unveils Precision Cancer Vaccine Breakthrough